Clinical Trial

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Study acronym: VISION
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic atrophy (GA) lesions in the treated eye in patients with GA secondary to age-related macular degeneration (AMD).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-01-03; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2025-02-27
Trial Details
NCT Number NCT06765980
Lead Sponsor Kriya Therapeutics, Inc.
Conditions Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment 62 participants
Start Date 2025-05-28
Primary Completion 2027-12-15 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-10